Date: 2012-09-27
Type of information: R&D agreement
Compound: monoclonal antibodies
Company: MAB Discovery (Germany) undisclosed US oncology focused biotech (USA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: MAB Discovery, a provider of therapeutic monoclonal antibodies, has initiated a research collaboration with a US oncology focused biotech . Employing its unique discovery platform, MAB Discovery will deliver a number of monoclonal antibodies to partner selected targets. The company employs natural immunization of wild type animals (rabbits and rats), followed by fully automated state of the art single B cell cloning and PCR methods to discover high affinity monoclonals covering extensive epitope space. Large and diverse panels of antibodies are created from B cells isolated at various times post immunization. Applications for the MAB Discovery platform range from discovery of monoclonals to novel and difficult targets (eg, GPCRs, ion channels), to finding agents suitable for ADC strategies, to making \"biobetters\", etc.
Financial terms: Financial terms were not disclosed.
Latest news:
